Dogwood Therapeutics, a biopharmaceutical company developing treatments for pain and neuropathy, will announce its first quarter 2026 financial results on May 14, 2026. The company is advancing two main drug candidates: Halneuron®, a non-opioid analgesic in Phase 2b targeting chemotherapy-induced neuropathic pain, and SP16 IV, a drug in early trials aimed at treating neuropathy and nerve damage from chemotherapy. Halneuron® has FDA fast track status, highlighting its potential significance. The upcoming financial report will provide insights into the company's progress and future prospects in these therapeutic areas.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
